LSD for Depression: What the Evidence Shows
One Trial Set Out to Treat Depression. It Narrowly Missed.

One randomised trial has ever set out to treat major depression with LSD. It narrowly missed. Everything else we know comes from trials that were studying something else.
The 60-Second Answer
LSD is not an approved treatment for depression anywhere in the world, and every positive result described here comes from a supervised clinical trial. Only one randomised trial has been designed specifically to treat major depressive disorder with LSD — 61 patients in Basel — and it missed its primary endpoint on the self-rated scale (−7.9 points, 95% CI −16.0 to 0.3, p = 0.059). A 2026 meta-analysis pooling five trials in 227 people found LSD reduced depression scores by a standardised 0.69, but most of those participants were enrolled for anxiety, not depression. Three phase 3 trials have now reported positive topline results by press release, with no peer-reviewed numbers yet. Promising, early, unapproved — and shadowed by a blinding problem nobody has solved.
Why psychedelics came back, and where LSD sits
For most of the past decade, the return of psychedelics to psychiatry has really been the return of psilocybin. It is the compound with the most trials, the most participants and the most scrutiny, and it still carries most of the evidence: a 2026 systematic review and meta-analysis of psilocybin-assisted therapy for depression pooled seven randomised trials in 522 participants.[8]
LSD has followed a step behind. The randomised evidence on LSD and depressive symptoms amounts to five trials in 227 participants — less than half the size of the psilocybin literature, and assembled, as the sections below show, mostly from people who were never enrolled for depression.[1]
Peak Human has already covered the two other agents in this space. Ketamine is where the depression evidence is strongest and where the drug is actually available to patients. MDMA-assisted therapy for PTSD is where a phase 3 programme reached the regulator and ran into an FDA rejection. LSD sits earlier on that road: a growing set of trials, a sponsor moving towards regulators, and not yet a single peer-reviewed phase 3 result.
What LSD is, and what “LSD-assisted therapy” means
Lysergic acid diethylamide was first semi-synthesised in Basel in 1938, from the ergot alkaloids produced by a fungus that grows on rye. Pharmacologically it is an agonist at the serotonin 5-HT2A receptor, the receptor most closely associated with the effects of the classic psychedelics.
For reading the trials, the model of treatment matters more than the molecule. In these studies LSD is given in one or two supervised dosing sessions, each lasting most of a working day, in a prepared setting, with trained personnel present throughout. Preparatory psychotherapy comes before and integration psychotherapy comes after. The one large exception, the MM120 trial described below, gave a single supervised dose without protocol-mandated psychotherapy. In none of them is LSD a tablet taken daily at home, and none of them resembles recreational use, where the screening, the setting and the supervision are all absent.
Two plain statements belong here. Nothing in this article is dosing guidance. And outside a clinical trial, LSD is a controlled substance. The entire evidence base discussed below comes from supervised administration inside a trial.
The one trial that set out to treat depression
Müller and colleagues at the University of Basel randomised 61 patients with moderate-to-severe major depressive disorder to two LSD dosing sessions four weeks apart — either 100 µg followed by 200 µg (30 patients) or 25 µg twice (31 patients) — with supportive psychotherapy in both arms.[2] The low dose, not an inert pill, was the control: a design choice meant to blunt the blinding problem described below, by giving both groups something they might notice. The primary endpoint was the change in the Inventory of Depressive Symptomatology, rated both by a clinician (IDS-C) and by the patient (IDS-SR), two weeks after the second session.
On the patients' own ratings, depression scores fell by 3.9 points in the low-dose group and 11.8 points in the high-dose group: a difference of −7.9 points (95% CI −16.0 to 0.3), an effect size of −0.5, with p = 0.059.[2] The confidence interval crosses zero. On the clinician-rated scale, scores fell by 3.6 and 12.9 points: a difference of −9.2 (95% CI −17.1 to −1.3), effect size −0.6, p = 0.023 — but that result was no longer significant once baseline depression scores were adjusted for (p = 0.086).[2]
Both outcomes stayed numerically consistent to the 12-week follow-up, and adverse events were comparable between the groups.[2]
One observation deserves to be made plainly, without being stretched. The scale that reached nominal significance, the IDS-C, was rated by the treating therapist. The patients' own ratings did not reach significance. That does not mean the clinician ratings were wrong; it means the two measures point in the same direction with different degrees of confidence, and the more independent of the two is the less certain one.
The authors describe the study as exploratory and say it supports a larger phase 3 trial. That is the correct reading. It was funded by the Gertrud Thalmann Fund, not by industry.[2]
The one trial designed to treat depression
Difference in IDS points, high dose vs low dose (negative favours high dose)
Müller et al. 2025, 61 patients with moderate-to-severe major depressive disorder, two LSD sessions four weeks apart: 100 µg then 200 µg versus 25 µg twice, both with supportive psychotherapy. Bars show the least-squares mean difference at the primary endpoint, two weeks after the second session, with 95% confidence intervals. The self-rated result crosses zero (p = 0.059). The clinician-rated result did not cross zero unadjusted (p = 0.023) but lost significance once baseline depression scores were accounted for (p = 0.086) — and it was rated by the treating therapist.
Source: Müller F et al., Med 2025;6(9):100725.
The anxiety trials, where most of the depression data actually come from
Most of what is known about LSD and depressive symptoms comes from trials of anxiety. The distinction matters, and it is easy to lose: evidence that a drug relieves anxiety, with depression measured along the way, is not evidence that it treats major depression.
The first modern randomised trial, by Gasser and colleagues in 2014, enrolled 12 patients with anxiety associated with a life-threatening disease, giving 200 µg to eight and a 20 µg active placebo to four. State anxiety fell significantly (p = 0.021, effect size 1.2) and trait anxiety showed a positive trend (p = 0.033, effect size 1.1), with no serious treatment-related adverse events.[5] A 12-month follow-up found the reductions sustained and no lasting adverse reactions.[6] It was an important trial. It was also twelve patients.
Holze and colleagues followed in 2023 with 42 patients who had anxiety with or without a life-threatening illness, randomised to two sessions of 200 µg LSD or placebo. Anxiety fell by 16.2 points on the STAI-Global at 16 weeks (95% CI −27.8 to −4.5, d = −1.18, p = .007). Comorbid depression also improved: the 21-item Hamilton Depression Rating Scale fell by 7.0 points (95% CI −10.8 to −3.2, d = −1.1, p = .0004) and the Beck Depression Inventory by 6.1 (95% CI −11.4 to −0.9, d = −0.72, p = .02).[4] This is the single largest contributor to the impression that LSD treats depression — and it was an anxiety trial, in which depression was a secondary outcome, in patients who were not selected for depression.
The largest LSD trial published so far, the MM120 phase 2b study in JAMA in 2025, randomised 198 adults with moderate-to-severe generalised anxiety disorder to a single dose of 25, 50, 100 or 200 µg of lysergide or to placebo, without protocol-mandated psychotherapy.[3] The indication was generalised anxiety disorder, not major depression. At four weeks, the 100 µg and 200 µg doses beat placebo on the Hamilton Anxiety Rating Scale by 5.0 points (95% CI −9.6 to −0.4) and 6.0 points (95% CI −9.8 to −2.0), against a minimal clinically important difference of 2.5 points. The 25 µg and 50 µg doses did not (−1.2, 95% CI −6.0 to 3.5; and −1.8, 95% CI −7.6 to 4.0).[3] The trial was sponsored by the drug's developer, and most of its authors were company employees.
Anxiety relief and the blind, dose by dose
What each dose did to anxiety
HAM-A points vs placebo at week 4
What each dose did to the blind
% reporting visual perceptual changes
Read down each panel, not across. The MM120 phase 2b trial randomised 198 adults with moderate-to-severe generalised anxiety disorder — not depression — to a single dose of lysergide or placebo. The two doses that separated from placebo on anxiety are the two doses that 93–100% of participants could identify from their own perceptual experience. Bars in panel A carry 95% confidence intervals; the dashed line marks the trial's pre-specified minimal clinically important difference of 2.5 points.
Source: Robison R et al., JAMA 2025;334(15):1358–1372.
What the meta-analysis adds — and what it cannot
A 2026 systematic review and meta-analysis in the Journal of Psychopharmacology, from a University of Toronto and CAMH group, screened 465 studies and pooled five randomised trials in 227 participants.[1] LSD significantly reduced depression scores against comparator, with a standardised mean difference of −0.69 (95% CI −0.96 to −0.42), or −0.65 (95% CI −0.92 to −0.38) after adjustment. Three of the five trials had a low risk of bias, heterogeneity was not significant, and all-cause discontinuation suggested reasonable acceptability.[1]
A standardised mean difference expresses the gap between groups in units of standard deviation, which is what allows trials using different rating scales to be combined. By the usual rough convention, 0.2 is small, 0.5 moderate and 0.8 large, so a pooled effect of about 0.65 to 0.69 sits between moderate and large. What it does not say is just as important. It is an effect on depression scores, assembled largely from trials whose participants were recruited for anxiety and in which depression was a secondary measure. And 227 people across five trials is a small evidence base by the standards of any approved antidepressant. The authors say exactly this: their own conclusion is that the review is limited by small sample size and that well-designed randomised trials are still needed.[1]
There is a second limit, which applies to the whole field. A short-term change on a depression rating scale is not the same claim as durable recovery. Rating scales are a reasonable and necessary way to run trials, but a number that moves over a few weeks is a measurement of symptoms at a point in time, not proof of lasting benefit. We make the general argument in our piece on why a biomarker isn't automatically a target.
The blinding problem
This is the methodological shadow over the entire field, and it can be measured. In the MM120 trial, visual perceptual changes — illusions, pseudo-hallucinations and hallucinations — were reported by 10.3% of the placebo group, 46.2% at 25 µg, 75.0% at 50 µg, 92.5% at 100 µg and 100% at 200 µg.[3] Virtually everyone who received an effective dose knew they had received it, and in practice so did the people around them.
A 2025 meta-analysis in JAMA Network Open quantified the consequence in the closest comparable literature. It concerns psilocybin, not LSD. Across 17 trials, the pre-to-post standardised mean change was 1.21 in psilocybin active arms (4 trials, 373 participants), 1.43 in esketamine active arms (2 trials, 573) and 1.28 in SSRI active arms (11 trials, 4,014) — statistically indistinguishable. The control arms were not: 0.50 in psilocybin trials, 1.12 in esketamine trials and 1.00 in SSRI trials. Trial population significantly moderated the control-arm effect (P = .005) but not the active-arm effect (P = .55).[7]
The authors' reading is that psilocybin's apparent advantage may be inflated because its control arms do unusually badly, not because its drug arms do unusually well. The intuition is not hard to see. People who volunteer for a psychedelic trial, receive an inert capsule and feel nothing have been told something about their allocation.
The Basel trial's low-dose control and the MM120 trial's four-dose design are both attempts to address this. Neither solves it.
It is the control arms that differ, not the drug arms
Standardised mean change in MADRS, baseline to ≤6 weeks
Error bars are ±1 standard error of the mean, not confidence intervals. This analysis is of psilocybin, not LSD — it is the closest quantification available of a problem that applies to every psychedelic trial, including the LSD trials in this article. The active arms are statistically indistinguishable across all three drug classes (P = .55 for the moderator test); the control arms are not (P = .005). The authors' reading is that psilocybin's apparent advantage may be overestimated because its control arms improve unusually little.
Source: Hieronymus F et al., JAMA Netw Open 2025;8(7):e2524119.
Phase 3: three positive toplines, no published numbers
The compound is now called DT120, formerly MM120: an orally disintegrating tablet of lysergide tartrate developed by Definium Therapeutics, previously MindMed. It holds FDA Breakthrough Therapy designation.[9][11] Three phase 3 studies have reported positive topline results by company press release.
In Panorama, in generalised anxiety disorder with 245 participants, the Hamilton Anxiety score fell by 9.8 points on 100 µg versus 4.7 on placebo at week 12, a 5.1-point difference (p < 0.0001, effect size d = 0.64). Response rates were 32% versus 14% and remission 15% versus 4%. Treatment-emergent adverse events occurred in 94.8% of people on the drug versus 62.9% on placebo, the commonest on dosing day being illusion (68%), nausea (37%) and headache (24%). Discontinuation was similar across arms and no drug-related serious adverse events were reported. These figures come from the company's press release of 14 September 2026.[10]
Voyage, in generalised anxiety disorder with 214 participants, and Emerge, in major depressive disorder with 149 participants given a single 100 µg dose or placebo and a primary endpoint of the MADRS at week 6, were also reported as positive in a company presentation on 4 November 2026.[11]
The important sentence is this one. Emerge is the first phase 3 result in major depressive disorder, and as of this writing its numbers exist only in a company announcement, not a peer-reviewed paper. A press release is a primary source about what a sponsor says it found. It is not the trial report, and it cannot be appraised. A further phase 3 trial in major depression, Ascend, is still enrolling.[12] Nothing is approved for any indication.
Safety, and who should not take this
The safety numbers that cut against a positive framing belong in the open. In the MM120 trial, nausea rose with dose to 60% at 200 µg, and visual perceptual changes to 100%.[3] The 2026 meta-analysis recorded severe adverse events possibly related to study parameters, including three hospitalisations and one episode of acute anxiety with delusions, across the pooled trials.[1] Holze's trial reported one treatment-related serious adverse event, an episode of acute transient anxiety, among 42 patients.[4] LSD also raises blood pressure and heart rate acutely.
Hallucinogen persisting perception disorder — lasting visual disturbance after hallucinogen use — is rare, poorly understood and has no established treatment. In a 2026 case report it persisted despite several medication trials in a young adult with comorbid bipolar I disorder.[13]
Classic psychedelics can precipitate or worsen psychosis, and they are contraindicated where there is a personal or family history of a psychotic or bipolar disorder; trial participants are screened for exactly this. Interactions with serotonergic medication matter too, and most people taking an SSRI or an MAOI were excluded from these trials.
If you are depressed and reading this, the right next step is a conversation with a clinician about the treatments that exist now — not an unsupervised experiment with a controlled substance, where none of the trial safeguards apply. Screening, a prepared setting, trained people in the room and follow-up afterwards are not decoration in these studies. They are part of the intervention.
Where this leaves things
LSD for depression is a real research question with a small, honestly reported evidence base. The one trial built for depression was encouraging and inconclusive. The pooled data lean positive but rest mostly on trials of anxiety. The phase 3 programme reports success in a form nobody outside the company can yet check. And underneath all of it sits a blinding problem that better trial design has narrowed but not closed.
When the phase 3 depression results appear in full in a peer-reviewed journal, this picture will need revisiting. Until then, it is fair to call LSD a promising investigational treatment, and inaccurate to call it an antidepressant.
The practical bottom line
- No regulator anywhere has approved LSD for depression or for anything else.
- The only randomised trial designed to treat major depression with LSD narrowly missed its primary endpoint.
- Most of the depression data come from trials of anxiety, in people not selected for depression.
- The pooled effect across five trials and 227 people is moderate-to-large and the evidence base is small.
- Every positive result comes from one or two supervised sessions with trained personnel present, not from self-directed use.
- A blinding problem that nobody has solved sits underneath all of it.
- The first phase 3 depression result exists only as a company announcement.
Frequently asked questions
Is LSD an approved treatment for depression?
No. It is not approved for any psychiatric indication in Canada, the United States or Europe. It is an investigational drug in clinical trials and a controlled substance outside them.
Has any trial tested LSD specifically for major depression?
One: a 61-patient randomised trial in Basel comparing high-dose with low-dose LSD plus supportive psychotherapy. It missed its primary endpoint on the self-rated scale (p = 0.059) and lost significance on the clinician-rated scale after adjustment for baseline severity.
What about the meta-analysis showing LSD reduces depression?
It pooled five randomised trials in 227 people and found a standardised mean difference of −0.69. Most of those participants were enrolled for anxiety; depression was usually a secondary outcome. Its own authors call the evidence base small.
How is LSD given in these trials?
One or two supervised dosing sessions, typically 100–200 µg, lasting most of a day, with preparation and integration psychotherapy and trained personnel present throughout. It is not taken daily and not taken alone.
What is "functional unblinding" and why does it matter?
Participants given an active psychedelic dose can tell — in one trial, 93–100% at the effective doses reported visual perceptual changes versus 10% on placebo. When people know their allocation, their expectations can move a symptom score, which makes the true drug effect hard to measure.
Is microdosing the same thing?
No. The doses used in these trials, 100–200 µg, produce clearly perceptible psychedelic effects. Controlled microdosing studies have generally used 5–20 µg, and the trial evidence described here says nothing about them.
References
- [1]Chiorean A, Kim HK, Lustig A, Husain MI. Efficacy, safety, and tolerability of lysergic acid diethylamide for the treatment of depressive symptoms: A meta-analysis and systematic review. J Psychopharmacol. 2026 Oct 30. PMID 42960975.
- [2]Müller F, Zaczek H, Becker AM, et al. Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial. Med. 2025;6(9):100725. PMID 40482648.
- [3]Robison R, Barrow R, Conant C, et al. Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial. JAMA. 2025;334(15):1358–1372. PMID 40906494.
- [4]Holze F, Gasser P, Müller F, Dolder PC, Liechti ME. Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study. Biol Psychiatry. 2023;93(3):215–223. PMID 36266118.
- [5]Gasser P, Holstein D, Michel Y, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014;202(7):513–520. PMID 24594678.
- [6]Gasser P, Kirchner K, Passie T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J Psychopharmacol. 2015;29(1):57–68. PMID 25389218.
- [7]Hieronymus F, López E, Werin Sjögren H, Lundberg J. Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression: A Meta-Analysis. JAMA Netw Open. 2025;8(7):e2524119. PMID 40736734.
- [8]Syed OA, Tsang B, Nestor SM, et al. Methodological moderators of psilocybin-assisted therapy in depression: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2026;183:106573. PMID 41587629.
- [9]Cubała WJ. DT120 (MM120): a single-dose orally disintegrating formulation of lysergide tartrate for generalized anxiety disorder. Expert Rev Neurother. 2026;26(11):1053–1063. PMID 42848417.
- [10]Definium Therapeutics. Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder. Press release, 14 September 2026.
- [11]Definium Therapeutics. Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress. Press release, 4 November 2026.
- [12]ClinicalTrials.gov. A Phase 3 Study Evaluating Oral DT120 Compared to Placebo in Adults With Major Depressive Disorder — Ascend. NCT07592689.
- [13]Notani S, Srinivasa V, Chaudhry S, Weiss A. Hallucinogen Persisting Perception Disorder in a Young Adult Case Report. Case Rep Psychiatry. 2026;2026:6605265. PMID 42694657.
